Zacks Investment Research·5 days ago
Zimmer Biomet (ZBH) is a Top-Ranked Value Stock: Should You Buy?Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zimmer Biomet Holdings, Inc.(ZBH)Earnings, Financials & Key Ratios
ZBH•NYSE
$89.41
25.2× P/E·Price updated Jul 7, 2026
AboutZimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as robotic, surgical and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.Show more
- Revenue$8.23B+7.2%
- EBITDA$2.46B+7.6%
- Net Income$705M-22.0%
- EPS (Diluted)3.55-19.9%
- Gross Margin61.62%-13.8%
- EBITDA Margin29.84%+0.4%
- Operating Margin16.55%-1.2%
- Net Margin8.57%-27.2%
- ROE5.6%-22.7%
ZBH Price & Volume
Zimmer Biomet Holdings, Inc. (ZBH) stock price & volume — 10-year historical chart
Loading chart...
Accelerating Revenue Growth Amidst Margin Volatility
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Accelerating
Profitability:Moderate
Financial:Healthy
Cash Flow:Stable
Primary Risk:Elective procedure volume sensitivity
Key Thesis Takeaways
- Zimmer Biomet is successfully pivoting toward high-growth orthopedic segments, evidenced by a 9.3% year-over-year revenue increase in 2026Q1.
- While the company maintains a healthy balance sheet with a 0.51 debt-to-equity ratio, investors should monitor persistent margin volatility and the capital-intensive nature of its consignment inventory model.
- Future performance hinges on the company's ability to translate top-line momentum into sustained operating margin expansion beyond the current 17.9% level.
Verdict Logic
while the 9.3% revenue growth in 2026Q1 is encouraging, the stock's 26.23 P/E ratio and historical margin volatility suggest investors should wait for more consistent operating leverage before increasing exposure.
ZBH Growth Metrics
Zimmer Biomet Holdings, Inc. (ZBH) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years3.22%
5 Years6.08%
3 Years5.85%
TTM9.23%
Profit CAGR
10 Years16.98%
5 Years-
3 Years44.98%
TTM-16.65%
EPS CAGR
10 Years29.87%
5 Years-
3 Years47.78%
TTM-14.82%
Return on Capital
10 Years4.08%
5 Years5.66%
3 Years6.87%
Last Year6.91%
ZBH Recent Earnings
Zimmer Biomet Holdings, Inc. (ZBH) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 11/12 qtrs (92%)
Q2 2026Latest
Apr 28, 2026Metric
Actual
Est
EPS
$2.09+12.4%
$1.86
Rev
$2.1B+0.8%
$2.1B
Q1 2026
Feb 10, 2026Metric
Actual
Est
EPS
$2.42+1.7%
$2.38
Rev
$2.2B+0.9%
$2.2B
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$1.90+1.6%
$1.87
Rev
$2.0B-0.5%
$2.0B
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$2.07+4.5%
$1.98
Rev
$2.1B+1.0%
$2.1B
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 28, 2026 | $2.09vs $1.86+12.4% | $2.1Bvs $2.1B+0.8% |
| Q1 2026 | Feb 10, 2026 | $2.42vs $2.38+1.7% | $2.2Bvs $2.2B+0.9% |
| Q4 2025 | Nov 5, 2025 | $1.90vs $1.87+1.6% | $2.0Bvs $2.0B-0.5% |
| Q3 2025 | Aug 7, 2025 | $2.07vs $1.98+4.5% | $2.1Bvs $2.1B+1.0% |
Based on last 12 quarters of dataView full earnings history →
Latest ZBH News
Recent stock market news and headlines for Zimmer Biomet Holdings, Inc. (ZBH)
Reuters·6 days ago
Medical device maker Zimmer Biomet to hire 500 in 3 years for tech centre in IndiaMedical device maker Zimmer Biomet plans to hire 500 employees over the next three years for its newly opened technology centre in Bengaluru, a senior executive said, as the U.S.-listed company expands its presence in India.
Zacks Investment Research·6 days ago
Pacira to Divest iovera Business to Zimmer Biomet in Up To $140M DealPCRX is set to sell its iovera franchise to ZBH in a deal worth up to $140M as it sharpens focus on biopharmaceutical growth.
Zacks Investment Research·Jun 24, 2026
ISRG vs. ZBH: Which Robotic Surgery Stock Offers Better Upside Now?ISRG stands out over ZBH as stronger revenue growth, rising procedure demand, and expanding AI-driven innovation support better upside in 2026.
Zacks Investment Research·Jun 18, 2026
Why Zimmer Biomet (ZBH) is a Top Momentum Stock for the Long-TermThe Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Peers Comparison
Key metrics vs top competitors for Zimmer Biomet Holdings, Inc. (ZBH)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $89.41 | $17.51B | 25.19 | 7.2% | 8.57% | 5.6% | 1.07% | |
| $313.38 | $120.14B | 37.31 | 11.16% | 13.21% | 15.1% | — | |
| $45.30 | $67.33B | 23.35 | 19.87% | 17.23% | 14.67% | — | |
| $83.83 | $107.63B | 22.47 | 8.43% | 13.2% | 9.78% | — | |
| $30.48 | $12.91B | 21.17 | 6.34% | 8.66% | 19.51% | — | |
| $78.83 | $10.63B | 20.11 | 16.65% | 18.92% | 13.04% | — |
Compare ZBH vs Peers
Zimmer Biomet Holdings, Inc. (ZBH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ZBH SEC Filings & Documents
Zimmer Biomet Holdings, Inc. (ZBH) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
Apr 28, 2026·SEC
Material company update
Apr 28, 2026·SEC
Material company update
Feb 10, 2026·SEC
10-K Annual Reports
210-Q Quarterly Reports
4Get notified when ZBH posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ZBH Frequently Asked Questions
Zimmer Biomet Holdings, Inc. (ZBH) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Zimmer Biomet Holdings, Inc.'s revenue?
Zimmer Biomet Holdings, Inc. (ZBH) reported $8.41B in revenue for fiscal year 2025. This represents a 796% increase from $939.0M in 1999.
How fast is Zimmer Biomet Holdings, Inc. growing?
Zimmer Biomet Holdings, Inc. (ZBH) grew revenue by 7.2% over the past year. This is steady growth.
Is ZBH profitable?
Yes, Zimmer Biomet Holdings, Inc. (ZBH) is profitable, generating $761.3M in net income for fiscal year 2025 (8.6% net margin).
Dividend & Returns
Does ZBH pay dividends?
Yes, Zimmer Biomet Holdings, Inc. (ZBH) pays a dividend with a yield of 1.07%. This makes it attractive for income-focused investors.
What is ZBH's return on equity?
Zimmer Biomet Holdings, Inc. (ZBH) has a return on equity (ROE) of 5.6%. This is below average, suggesting room for improvement.
What is Zimmer Biomet Holdings, Inc.'s free cash flow?
Zimmer Biomet Holdings, Inc. (ZBH) generated $1.84B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.